Home › Macular Degeneration › NCT06924021
Age-Related Macular Degeneration Benchmark Imaging Dataset (ABID)
RecruitingObservational studyHealthy volunteers welcome
Who can join
Ages 50 and older · All sexes · Healthy volunteers welcome
Full eligibility criteria
Inclusion Criteria: * Participants greater than or equal to 50 years of age at time of signing Informed Consent Form * Willing to comply with all study procedures and sign the Informed Consent Form (ICF) * Individuals with normal healthy eyes or diagnosed with any stage of Age-Related Macular Degeneration (treatment naïve patients with early, intermediate, or late AMD). The diagnosis and eligibility review will be confirmed by Central Reading Center. Exclusion Criteria: * Therapeutic treatment for any type of AMD, in either eye. Supplements, such as AREDS2 formula, are allowed. * Unable to acquire adequate quality images, as evaluated by the Central Reading Center * Severe vision loss requiring urgent surgery * Contraindicated for acquiring retinal images due to narrow anterior chamber angles or hypersensitivity to light * A systemic or ocular condition that in the opinion of the Investigator would preclude participation in the study * Unwilling to sign informed consent form * Currently or previously enrolled in an interventional AMD clinical trial
About the study
1000 participants from up to 25 international locations who are at least 50 years old with either healthy eyes or a diagnosis of Age-Related Macular Degeneration (AMD) will be consented to provide images of their eyes for a new dataset. This dataset is an important step in developing an Artificial Intelligence (AI) based screening tool for AMD.
What is being tested
- Retinal Imaging (other)
Sponsor: University of Wisconsin, Madison · Participants: 1,000 · Started: May 12, 2025
Contact the study team
- Wisconsin Reading Center · Phone: 1-608-262-1334
Official record on ClinicalTrials.gov — NCT06924021
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.